December 7, 2020 08:55 AM EST
FDA+

Amid a record bad year, Bel­licum keeps tak­ing its lumps as FDA slams tri­al hold on CAR-T hope­ful

Kyle Blankenship

It’s been no less than a dis­as­trous year for Hous­ton biotech Bel­licum Phar­ma­ceu­ti­cals af­ter tak­ing a scalpel to its pipeline and dump­ing a vast ma­jor­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

Up­dat­ed: No­vo Nordisk sees growth slow­ing this year, plans Ca­griSe­ma fil­ing for 2026

A service from the Financial Times